Arts and Crafts Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The aspergillosis treatment market size has grown strongly in recent years. It will grow from $3.14 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to diagnostic advancements, demand for antifungal medications, increased incidence, invasive procedures.

The aspergillosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.28 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for transplant medicine, prevalence of hematologic malignancies, increasing investments in research and development, public health initiatives. Major trends in the forecast period include antifungal resistance, targeted therapies, therapeutic drug monitoring, drug development.

The growing prevalence of fungal infections is anticipated to drive the expansion of the aspergillosis treatment market. Fungal infections, or mycoses, are diseases caused by fungi that can affect both humans and animals. Aspergillosis, a specific type of fungal infection, can impact various parts of the body, including the respiratory system, lungs, brain, kidneys, and other organs. Treatments for aspergillosis, such as the antifungal medication voriconazole, aim to control infection, relieve symptoms, prevent complications, and enhance overall health. For example, in September 2023, the UK Health Security Agency reported an increase in bloodstream yeast infections in England, with cases rising from 3.8 per 100,000 people in 2021 to 4 in 2022. Consequently, the rising incidence of fungal infections is fueling growth in the aspergillosis treatment market.

Increasing healthcare expenditures are expected to drive growth in the aspergillosis treatment market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance. An increase in these expenditures supports the advancement of more effective treatments and medical technologies for managing aspergillosis. For example, in May 2023, the Office for National Statistics reported that healthcare spending in the UK reached approximately $362.08 billion (£292 billion), marking a 5.6% nominal increase. Additionally, spending on long-term health and social care rose by 2.8% in real terms in 2022. As a result, rising healthcare spending is bolstering the aspergillosis treatment market's growth.

Prominent companies in the aspergillosis treatment sector are dedicated to introducing cutting-edge drugs and solutions to maintain their competitive edge. These breakthroughs in drug development broaden the spectrum of treatment options available for aspergillosis. An example of this progress is the introduction of posaconazole oral suspension, which offers more precise and efficient treatment choices for patients. Notably, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Posaconazole oral suspension in the US for treating aspergillosis. This medication is particularly relevant for patients with severely compromised immune systems, like hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), who are at high risk of developing invasive aspergillus and candida infections. Furthermore, posaconazole oral suspension is recommended for oropharyngeal candidiasis (OPC), particularly when it proves refractory to itraconazole and fluconazole.

In May 2022, F2G Ltd., a pharmaceutical company based in England, entered into a partnership with Shionogi & Co., Ltd. to advance the development and commercialization of olorofim, an innovative antifungal treatment for invasive fungal infections, including invasive aspergillosis, across Europe and Asia. Shionogi & Co., Ltd., headquartered in Japan, specializes in developing treatments for invasive aspergillosis and other serious fungal infections.

Major companies operating in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Ltd., Bruker Corporation, Hikma Pharmaceuticals PLC.

North America was the largest region in the aspergillosis treatment market in 2024. The regions covered in aspergillosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aspergillosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aspergillosis treatment market consists of sales of immunotherapy drugs, echinocandin and azole antifungals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Aspergillosis treatment refers to addressing a fungal infection caused by the aspergillus species, with the specific approach depending on the severity and type of the disease. Aspergillosis can pose a serious and potentially life-threatening threat, particularly to individuals with compromised immune systems.

The primary categories of aspergillosis treatment encompass allergic aspergillosis, chronic aspergillosis, invasive aspergillosis, and other variants. Allergic aspergillosis, also recognized as allergic bronchopulmonary aspergillosis (ABPA), denotes a specific allergic response to the Aspergillus fungus, most frequently associated with Aspergillus fumigatus. Various classes of drugs are utilized, including corticosteroids, antifungal medications, and others. These treatments can be administered through oral, injectable, and alternative routes, and are distributed through a range of channels such as hospital pharmacies, retail pharmacies, and others.

The aspergillosis treatment market research report is one of a series of new reports that provides aspergillosis treatment market statistics, including aspergillosis treatment industry global market size, regional shares, competitors with an aspergillosis treatment market share, detailed aspergillosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the aspergillosis treatment industry. This aspergillosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.